News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ipsen (IPN.PA) Announces Second Resupply Of Increlex® (Mecasermin [Rdna Origin] Injection) In The U.S. In 2014



8/26/2014 8:30:08 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BASKING RIDGE, N.J.--(BUSINESS WIRE)--Ipsen N.A. (Euronext: IPN; ADR: IPSEY) today announced that a new supply of Increlex® will be available starting in September 2014. In collaboration with the U.S. Food and Drug Administration (FDA), Ipsen is releasing a second batch of Increlex® in 2014. The first batch was made available for distribution in June of 2014.

“We are pleased that an additional supply of Increlex® has been released for distribution to treat pediatric patients with severe primary IGF-1 deficiency, a condition which can cause permanent short stature,” said Cynthia Schwalm, President and CEO of Ipsen N.A. “These children depend on this product for the treatment of this rare and debilitating condition.”

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
Ipsen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES